No connection

Search Results

ABBV vs NVCR

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
NVCR
NovoCure Limited
BEARISH
Price
$12.17
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
NVCR
--
Forward P/E
ABBV
15.42
NVCR
-10.44
P/B Ratio
ABBV
-146.66
NVCR
4.02
P/S Ratio
ABBV
6.5
NVCR
2.11
EV/EBITDA
ABBV
15.27
NVCR
-8.77

Profitability

Gross Margin
ABBV
71.46%
NVCR
74.8%
Operating Margin
ABBV
35.5%
NVCR
-21.33%
Profit Margin
ABBV
4.0%
NVCR
-20.79%
ROE
ABBV
137.96%
NVCR
-38.89%
ROA
ABBV
9.59%
NVCR
-9.06%

Growth

Revenue Growth
ABBV
9.1%
NVCR
8.1%
Earnings Growth
ABBV
-88.7%
NVCR
--

Financial Health

Debt/Equity
ABBV
--
NVCR
0.73
Current Ratio
ABBV
0.72
NVCR
2.9
Quick Ratio
ABBV
0.47
NVCR
2.51

Dividends

Dividend Yield
ABBV
3.05%
NVCR
--
Payout Ratio
ABBV
490.15%
NVCR
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
NVCR BEARISH

NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.

Strengths
High Gross Margin (74.80%) indicating strong product value
Strong short-term liquidity with a Current Ratio of 2.90
Improving EPS growth YoY (+63.9%) despite remaining negative
Risks
Weak financial health as indicated by Piotroski F-Score (3/9)
Severe long-term value destruction (-93.7% 5-year return)
Negative operating and profit margins (-21.33% and -20.79%)

Compare Another Pair

ABBV vs NVCR: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and NovoCure Limited (NVCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile